UniQuest — Technology Transfer Company of The University of Queensland

UniQuest Pty Limited is the wholly owned technology-transfer and commercialisation company of The University of Queensland (UQ) in Brisbane, Australia, operating since 1984. It manages the pipeline from patent filing through licensing to established companies and the creation of spin-out firms, in which it typically takes an equity stake of up to about 38% — notably, UQ does not allow academic founders to hold equity directly in spin-outs, a policy meant to manage conflicts of interest around taxpayer-funded research.
Its best-known outcome is licensing the intellectual property behind the Gardasil cervical-cancer (HPV) vaccine, patented by UniQuest in 1991 and sub-licensed via CSL to Merck in 1996; UQ's own audited Annual Report 2021 documents a specific $5.0 million (15.9%) year-on-year rise in royalty and licence-fee revenue attributed to Gardasil. UniQuest's own reporting credits its broader portfolio with 141 spin-out companies, 360+ granted US patents, 240+ active licences and over A$1 billion returned to UQ since 2002 — figures echoed in less granular form by Times Higher Education, which places UQ in the global top 10% for IP-revenue generation.
The record carries real caveats. UQ's own 2018 reporting found only 46% of its 100-plus historical spin-outs remained operationally active or had exited successfully, and outcomes are heavily concentrated in a few blockbuster deals — Gardasil, the Spinifex Pharmaceuticals sale to Novartis (US$1 billion, 2015), and a 2025 Vicebio-Sanofi deal worth up to US$1.6 billion — rather than spread evenly across the portfolio. Industry commentary (Global University Venturing) also frames UQ's no-founder-equity policy as a debated outlier among Australian universities, one that may reduce founder incentives even as it addresses conflict-of-interest concerns.

Read the full analysis: https://news.uq.edu.au/2025-07-billion-dollar-deal-takes-uq-vaccine-tech-world